Lisocabtagene Maraleucel (Breyanzi)

CDA-AMC recommends that Breyanzi be reimbursed by public drug plans for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL), and DLBCL arising from follicular lymphoma, who have disease that is refractory to first-line chemoimmunotherapy or who experience relapse within 12 months of first-line chemoimmunotherapy, and who are candidates for autologous hematopoietic stem cell transplant (HSCT), if certain conditions are met. Breyanzi should only be covered to treat adults with DLBCL not otherwise specified, PMBCL, HGBCL, or DLBCL arising from follicular lymphoma who do not experience a response to first-line therapy or who experience relapse within 12 months of first-line therapy; who are eligible for autologous HSCT; and who are in relatively good health (as measured by performance status). Breyanzi should only be reimbursed for patients who have not yet been treated with chimeric antigen receptor (CAR) T-cell therapy, if it is prescribed and administered by clinicians with expertise in lymphomas and CAR T-cell therapy in a hospital setting with adequate resources, and if the cost of Breyanzi is not more than that of axicabtagene ciloleucel (axi-cel). It must also be feasible to administer Breyanzi.